- Home
- ZNTL vs GDO Comparison
ZNTL vs GDO Comparison
Compare ZNTL & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- GDO
- Stock Information
- Founded
- ZNTL 2014
- GDO 2009
- Country
- ZNTL United States
- GDO United States
- Employees
- ZNTL N/A
- GDO N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- GDO Finance Companies
- Sector
- ZNTL Health Care
- GDO Finance
- Exchange
- ZNTL Nasdaq
- GDO Nasdaq
- Market Cap
- ZNTL 105.8M
- GDO 86.3M
- IPO Year
- ZNTL 2020
- GDO N/A
- Fundamental
- Price
- ZNTL $1.32
- GDO $11.61
- Analyst Decision
- ZNTL Buy
- GDO
- Analyst Count
- ZNTL 7
- GDO 0
- Target Price
- ZNTL $8.60
- GDO N/A
- AVG Volume (30 Days)
- ZNTL 961.9K
- GDO 39.4K
- Earning Date
- ZNTL 08-08-2025
- GDO 01-01-0001
- Dividend Yield
- ZNTL N/A
- GDO 9.81%
- EPS Growth
- ZNTL N/A
- GDO N/A
- EPS
- ZNTL N/A
- GDO N/A
- Revenue
- ZNTL $26,865,000.00
- GDO N/A
- Revenue This Year
- ZNTL N/A
- GDO N/A
- Revenue Next Year
- ZNTL N/A
- GDO N/A
- P/E Ratio
- ZNTL N/A
- GDO N/A
- Revenue Growth
- ZNTL N/A
- GDO N/A
- 52 Week Low
- ZNTL $1.01
- GDO $11.21
- 52 Week High
- ZNTL $5.70
- GDO $13.04
- Technical
- Relative Strength Index (RSI)
- ZNTL 47.15
- GDO 64.79
- Support Level
- ZNTL $1.31
- GDO $11.55
- Resistance Level
- ZNTL $1.54
- GDO $11.65
- Average True Range (ATR)
- ZNTL 0.14
- GDO 0.10
- MACD
- ZNTL -0.00
- GDO 0.01
- Stochastic Oscillator
- ZNTL 31.36
- GDO 89.63
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.